- Home
- » Tags
- » Momelotinib
Top View
- Translating Jaks to Jakinibs Massimo Gadina, Danielle A
- Performance in Delivering Clinical Research (Q3, 2016/17)
- Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development S
- Downloaded from Chemaxon (Budapest, Hungary)[115,171-183]
- Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
- Galapagos Turns the Tables on Abbvie, Courtesy of Gilead
- Setback for JAK2 Inhibitors
- Aabc-304649-Chemoinformatic-An
- Tracks 1-12 Elias Jabbour, MD Select Excerpts from the Interview Tracks 1
- 2020 Medicines in Development ꟷ Cancer
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- CTI Biopharma 2018 Annual Report
- The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
- Rheumatology News®
- A Phase 2 Study of Momelotinib, a Potent JAK1 and JAK2 Inhibitor, in Patients with Polycythemia Vera Or Essential Thrombocythemia
- Annexes to the 2019 Annual Report of the European Medicines Agency
- 1518 JAK2 46216796 C28H32N4O3 472.58 1/7 4.499 Myelodysplastic Syndromes, Myelofibrosis
- Persistence of Myelofibrosis Treated with Ruxolitinib
- Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era Peerv
- Advances in Llm
- 1 Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant
- Comprehensive Kinase Profile of Pacritinib, a Nonmyelosuppressive Janus Kinase 2 Inhibitor
- ( 12 ) Patent Application Publication
- TAG Mail – 17 Dec 2020
- Oncology Drugs in the Pipeline
- UCI Health Cancer Center — Newport Clinical Trials
- Interaction of 2,4-Diaminopyrimidine–Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters S
- WO 2018/073754 Al 26 April 2018 (26.04.2018) W !P O PCT
- Oncology Drugs in the Pipeline
- Abstract #1663 MOMENTUM Phase 3 Clinical Trial Background Momelotinib's Mechanism of Action Methods and Results Conclusions
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Februar 2021 ·
- WO 2016/151499 Al 29 September 2016 (29.09.2016) P O P C T
- JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted T Herapy in Non−Small Cell Lung Cancer
- Changing the Treatment Story in Myelofibrosis New Science and More Choices for Challenging Cases in the JAK Inhibitor Era
- Selective Targeting of JAK/STAT Signaling Is Potentiated by Bcl-Xl Blockade in IL-2–Dependent Adult T-Cell Leukemia
- Efficacy and Tolerability of Janus Kinase Inhibitors In
- Gilead Announces Top-Line Results from Two Phase 3 Studies Evaluating Momelotinib for Patients with Myelofibrosis November 16, 2
- Targeting the JAK/STAT Pathway in Solid Tumors
- Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes
- Momelotinib for Myelofibrosis
- Comparison of Momelotinib, Pacitinib and Ruxolitinib
- Annual Report 2015 Annexes